,,,trastuzumab deruxtecan
astrazeneca,daiichi sankyo,astrazeneca,daiichi sankyo
['destiny,breast,4', 'breast', 'enhertu', 'destiny-breast04', 'astrazeneca']
 updates: has presented the potentially practice-changing results of the destiny-breast04 trial of #enhertu in her2-low metastatic breast cancer vs. treatment of physician s choice. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry